Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 22, 20 December 2023
Open
Access | Article
The brief introduction of CAR T-cell: From mechanism to application
* Author to whom correspondence should be addressed.
Abstract
Chimeric antigen receptor T-cell (CAR-T) gene therapy is a newly developed solution to fight tumor cells. The therapy develops from the combination of the immunity and cell bioengineering, taking advantage of the cell killing function of T-cells, scientists modify them with a bioengineering method to target specific cells. In recent days, this therapy shows great results in several trials especially in hematological malignancies. However, there are still many obstacles, such as toxicities, that need to be overcome. Taking the promising potentials of CAR T-cell gene therapy, it is still a revolutionary step in the improvement of immunotherapy. In this paper, we focus on the structure and target antigens of CAR T-cell, summarize the generations of CAR T-cell gene therapies, as well as list out the FDA approved treatments using CAR. Most importantly, we will discuss the past advancements, recent innovations, and the existing factors that still prevent CAR T-cells from becoming the first line treatment for cancers.
Keywords
CAR T-cells, immunotherapy, toxicities, tumor therapy
References
1. “Car T Cells: Timeline of Progress,” Memorial Sloan Kettering Cancer Center.
2. “CAR T Cell Therapy,” Penn Medicine.
3. “Car T-Cell Therapy: Procedure, Prognosis & Side Effects,” Cleveland Clinic.
4. Ahmad, U., et al., “Chimeric Antigen Receptor T Cell Structure, Its Manufacturing, and Related Toxicities; a Comprehensive Review,” (2022).
5. Mehrabadi, A. Z., et al., “Therapeutic Potential of Car T Cell in Malignancies: A Scoping Review,” (2022).
6. Abbott, R. C., et al., “Finding the Keys to the Car: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.” (2020).
7. Kandra, P., et al., “Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer,” Frontiers, (2022).
8. Mikhael, J., et al., “Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions To Access,” (2022).
9. Sterner, R. C. and Sterner, R. M., “Car-T Cell Therapy: Current Limitations and Potential Strategies,” Nature News, (2021).
10. “Chimeric Antigen Receptor (CAR) T-Cell Therapy,” Leukemia & Lymphoma Society.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-217-6
- ISBN (Online)
- 978-1-83558-218-3
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/22/20230959
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited